Safety and immunogenicity of human papillomavirus vaccination in juvenile patients with rheumatic diseases by Heijstek, MW et al.
ORAL PRESENTATION Open Access
Safety and immunogenicity of human
papillomavirus vaccination in juvenile patients
with rheumatic diseases
MW Heijstek
1*, N Groot
1, M Scherpenisse
2, C Tacke
1, G Berbers
1, F van der Klis
2, NM Wulffraat
1
From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011
Aim
To assess the safety and immunogenicity of the bivalent
HPV vaccine (Cervarix) in patients with Juvenile Idio-
pathic Arthritis (JIA), Systemic Lupus Erythematosus
(SLE) and Juvenile Dermatomyositis (JDM).
Methods
A prospective controlled observational trial was initiated
in female patients and healthy controls aged 12-18
years. Patients and controls were vaccinated (0, 1, and 6
months) and followed for 12 months. HPV16 and 18-
specific antibody concentrations were measured using a
fluorescent microspheres-based multiplex immuno-assay
after 12 months. Adverse events (AE’s) 2 weeks after
each vaccination were systematically documented in dia-
ries. In patients, medication use was monitored and dis-
ease activity was measured by the Juvenile Arthritis
Disease Activity Score of 27 joints (JADAS-27), SLE Dis-
ease Activity Index, or the Childhood Myositis Assess-
ment Scale.
Results
58 patients (45 JIA, 8 SLE, 5 JDM) and 51 healthy con-
trols are currently included, patients are still being
enrolled. The percentage of patients responding to vac-
cination (response rate) was similar in patients and con-
trols. However, HPV16 antibodies were lower in JIA
(5119 LU/ml, p=0.037), SLE (1461 LU/ml, p=0.002) and
JDM patients (3233 LU/ml, p=0.262) compared with
healthy controls (8799 LU/ml). HPV18 antibodies were
similar in JIA patients and controls (2764 LU/ml versus
2522 LU/ml, p=0.732); SLE (730 LU/ml, p=0.030) and
JDM patients (1147 LU/ml, p=0.384) showed markedly
lower antibody levels. MTX-use did not lower vaccine
responses.
The median JADAS-27 did change considerably
between visits (1.9-2.5), but JADAS-27 was significantly
elevated at 7 months (p=0.001) due to one outlier. SLE
and JDM disease activity remained similar. AE’sw e r e
similar in patients and controls.
Conclusion
Cervarix was safe in girls with rheumatic diseases. The
response rates were similar in patients and healthy con-
trols, whereas antibody concentrations were markedly
lower in SLE and JDM patients.
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